A Study of SYS6020 Injection in Refractory Active Systemic Lupus Erythematosus

PHASE1Not yet recruitingINTERVENTIONAL

Enrollment

Participants

Timeline

Start Date

December 26, 2024

Primary Completion Date

January 29, 2029

Study Completion Date

January 29, 2029

Conditions

Refractory Active Systemic Lupus Erythematosus

Interventions

DRUG

SYS6020

BCMA Chimeric Antigen Receptor T Cell（SYS6020）Injection Intravenous infusion

All Listed Sponsors

lead

CSPC ZhongQi Pharmaceutical Technology Co., Ltd.

INDUSTRY